Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer metabolism

Melting KRAS resistance

Nature Chemical Biology (2025)Cite this article

Subjects

Cereblon-based molecular glue degraders provide a powerful strategy to target previously intractable proteins. This approach has now enabled selective elimination of a metabolically essential zinc finger transcription factor that drives resistance to KRAS inhibition in pancreatic cancer.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting ZBTB11 to overcome KRAS inhibitor resistance in PDAC.

References

  1. Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Cancer Discov. 12, 924–937 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zhao, Z., Mei, Y., Wang, Z. & He, W. Cancers 15, 62 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tran, N. L. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-025-01978-1 (2025).

    Article  PubMed  Google Scholar 

  4. Sievers, Q. L. et al. Science 362, eaat0572 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B. & Thoma, N. H. Annu. Rev. Pharmacol. Toxicol. 64, 291–312 (2024).

    Article  CAS  PubMed  Google Scholar 

  6. Krönke, J. et al. Science 343, 301–305 (2014).

    Article  PubMed  Google Scholar 

  7. Bonazzi, S. et al. Cell Chem. Biol. 30, 235–247.e12 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Krönke, J. et al. Nature 523, 183–188 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Matyskiela, M. E. et al. Nature 535, 252–257 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Broad DepMap. DepMap 23Q4 Public. Figshare+ https://doi.org/10.25452/figshare.plus.24667905.v2 (2023).

Download references

Author information

Authors and Affiliations

  1. Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA

    Shatha AbuHammad & Mikolaj Slabicki

  2. Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Shatha AbuHammad & Mikolaj Slabicki

  3. Department of Medicine, Harvard Medical School, Boston, MA, USA

    Mikolaj Slabicki

Authors
  1. Shatha AbuHammad
    View author publications

    Search author on:PubMed Google Scholar

  2. Mikolaj Slabicki
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Mikolaj Slabicki.

Ethics declarations

Competing interests

M.S. has received research funding from Calico Life Sciences LLC. S.A. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

AbuHammad, S., Slabicki, M. Melting KRAS resistance. Nat Chem Biol (2025). https://doi.org/10.1038/s41589-025-01980-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41589-025-01980-7

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer